Email Address:
  
  Password:
  
  

Exhibit 10.8

AMENDMENT NUMBER TWO TO CLINICAL TRIAL AGREEMENT

THIS AMENDMENT NUMBER TWO TO THE CLINICAL TRIAL AGREEMENT (the “Amendment”) is effective December 1, 2009 (“Effective Date”) The General Hospital Corporation d/b/a Massachusetts General Hospital, a not-for-profit corporation organized under the laws of Massachusetts with its principal place of business at 55 Fruit Street, Boston, MA 02114 (“Institution”) and CytoDyn, Inc., a publicly traded corporation organized under the laws of Colorado with its principal place of business at 1511 Third Street, Santa Fe, New Mexico 87505 (“Company”).

RECITALS

 

 

A.

INSTITUTION has previously entered into a Clinical Trial Agreement to perform the study protocol entitled “An observational study to determine the in-vitro immunologic and virology activity of Cytolin,” with Company on 28 September 2009 (the “Agreement”) and amended it on October 14, 2009.

 

 

B.

The parties now desire to further amend the Agreement


This is only a partial view of this document. We have millions of legal documents and clauses drafted by top law firms. learn more search for free browse for free learn more